Mometasone furoate inhibits growth of acute leukemia cells in childhood by regulating PI3K signaling pathway

Objectives: Acute lymphoblastic leukemia (ALL) is the most common cancer before the age of 15 years, seriously endangering the health of children. The main treatment for Childhood ALL was pharmacotherapy. But these drugs have many side effects and some of them could develop drug resistance quickly. Mometasone furoate (MF) is an efficient glucocorticoid for topical treatment of inflammation on the skin, lung and nose.

Methods: In this study, we investigated whether the MF had effects on ALL cells proliferation and migration.

Results: The CCK-8 proliferation test showed that the cell viability was the lowest at 25?nM MF treatment and the increased OD value was time-dependent. In transwell assay, the number of CCRF-CEM cells was reduced in MF treated group. We found the expression of anti-apoptotic protein bcl-2 decreased the expression of pro-apoptotic protein caspase3 and bax increased in CCRF-CEM cell line treated with MF. The expression of p-AKT, p-mTOR, p70S6?K, vascular endothelial growth factor and CyclinD1 were decreased in MF treated group.

Conclusion: This study reveals that MF can inhibit proliferation and invasion/migration and induce apoptosis in Childhood ALL cells, which may be regulated by Phosphatidylinositol 3-kinase signaling pathway. These results suggest MF may be a potential new drug target for clinical ALL treatment.     

Evidence of association between single-nucleotide polymorphisms in lipid metabolism-related genes and type 2 diabetes mellitus in a Chinese population

Background: Type 2 diabetes mellitus (T2DM) is a complex chronic metabolic disorder triggered by insulin resistance in peripheral tissues. Evidence has shown that lipid metabolism and related genetic factors lead to insulin resistance. Hence, it is meaningful to investigate the association between single-nucleotide polymorphisms (SNPs) in lipid metabolism-related genes and T2DM.Methods: A total of 1,194 subjects with T2DM and 1,274 Non-diabetic subjects (NDM) were enrolled. Five SNPs in three genes (rs864745 in JAZF1, rs35767 in IGF1, and rs4376068, rs4402960, and rs6769511 in IGF2BP2) that contribute to insulin resistance involving lipid metabolism were genotyped using the MassArray method in a Chinese population.Results: The allele and genotypes of rs6769511 in IGF2BP2 were associated with T2DM (P=0.009 and P=0.002, respectively). In inheritance model analysis, compared with the T/T-C/T genotype, the C/C genotype of rs6769511 in IGF2BP2 was a risk factor for the development of T2DM (P<0.001, odds ratio [OR] =1.76; 95% confidence interval [CI]: 1.29-2.42). Haplotype analysis revealed associations of the rs4376068-rs4402960-rs6769511 haplotypes in IGF2BP2 with the development of T2DM (P=0.015). Additionally, rs4376068C-rs4402960T-rs6769511C was a risk haplotype for T2DM (OR=1.179; 95% CI: 1.033-1.346).Conclusion: The rs6769511 in IGF2BP2 was associated with T2DM susceptibility, and the rs4376068-rs4402960-rs6769511 haplotypes in IGF2BP2 was associated with the development of T2DM in a Chinese population.     

医学博士生延期毕业影响因素分析

目的调查“双一流”建设高校医学博士生延期毕业的影响因素，为改进医学博士生培养模式、降低延期毕业率提供指导依据。方法通过“学生个体特征”“关键培养环节”“导学互动”以及“心理建设与社会支持”4个维度，构建医学博士生延期毕业影响因素理论模型，利用二元logistic回归进行统计分析。结果选择跨学科读博的研究生更易发生延期（OR=8.80,P=0.01），以“申请考核”（OR=9.06,P<0.01）、“硕博连读”（OR=5.41,P=0.02）方式录取的博士生较以直博生方式录取的博士生发生延期毕业风险更高；关键培养环节中“论文写作培训与科研能力训练”（OR=0.33,P=0.01）、“资助程度”（OR=0.42,P=0.05）以及导学互动中“导师及科研团队的指导”（OR=0.23,P=0.03）和“科研投入”（OR=0.56,P<0.01）均对正常毕业存在负向影响关系。结论建立科学合理的生源选拔机制、形成良好的导学互动、科学系统的写作训练、充实的资助以及国内国际学术交流有益于降低医学博士生的延期风险。下一步应加强关键培养环节的质量监控，完善医学博士生分流机制，强化问题导向，实现“导师+院系联动”保证培养质量。     

经脐单部位腹腔镜治疗罕见儿童疝体会

目的探索经脐单部位腹腔镜手术在罕见儿童疝的临床应用。 方法回顾性分析2014年10月至2017年10月山西省儿童医院11例罕见疝患儿行腹腔镜手术的临床资料。其中男性患儿7例，女性患儿4例，年龄1～12岁。其中腹股沟滑疝5例，腹股沟直疝5例及股疝1例。 结果本组患儿均经脐单部位完成，手术时间20～39 min，无中转开放手术，均术后第2天出院。术后无切口感染、阴囊血肿发生。 结论经脐单部位腹腔镜手术治疗罕见小儿疝安全、微创、恢复快，值得推广应用。     

海洋生物医用材料的临床应用和安全性评价

目的： 对海洋生物医用材料在医疗领域的应用情况和海洋生物材料来源医疗器械的安全性评价趋势进行分析，为推进该材料的临床转化提供参考。方法： 归纳海洋生物医用材料的分类和应用，介绍该材料的安全性评价的程序要点，探讨其安全性评价中面临的挑战。结果与结论： 常用的海洋生物医用材料主要为多糖和蛋白质，在创伤修复和组织工程领域应用广泛。海洋生物医用材料具有生物活性和良好的生物相容性，对此类材料的安全性评价应根据材料特性和预期用途，科学制定评价程序和选择检验方法。